GlassScriptPhysician profile
Jeffrey P Colnes
NPI 1649204504
$21,673.80
in general payments reported to CMS, 2019-2025
31 companies · $1,091 in 2025
The $1,091 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,510 · 2020: $1,214 · 2021: $1,365 · 2022: $4,919 · 2023: $3,968 · 2024: $3,607 · 2025: $1,091.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,740 · Travel and Lodging: $3,846 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,739.84 |
| Travel and Lodging | $3,846.06 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $9,067.49 | 2019-2025 | Aveir, Mitraclip, Dragonfly Opstar |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $7,022.65 | 2019-2025 | Lifevest |
| Medtronic Vascular, INC. | $891.00 | 2019-2020 | |
| Abiomed | $570.02 | 2019-2025 | Impella |
| Boston Scientific Corporation | $520.33 | 2019-2021 | |
| Medtronic, INC. | $468.67 | 2021-2024 | Pulseselect, Onyx Frontier, Na |
| Janssen Pharmaceuticals, INC | $347.38 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $338.52 | 2019-2025 | Camzyos |
| Novartis Pharmaceuticals Corporation | $279.29 | 2019-2024 | |
| Lantheus Medical Imaging, INC. | $212.70 | 2023 | Definity |
| Astrazeneca Pharmaceuticals LP | $200.86 | 2019-2022 | |
| Shockwave Medical, INC | $193.28 | 2022 | |
| Pfizer INC. | $186.27 | 2019 | |
| Stryker Corporation | $175.73 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Sanofi-Aventis U.S. LLC | $166.39 | 2019-2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Elutia, INC. | $147.77 | 2021 | |
| Cardiovascular Systems INC. | $145.50 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $121.25 | 2019-2024 | Opsumit, Uptravi |
| Bayer Healthcare Pharmaceuticals INC. | $119.87 | 2022 | |
| Atricure, INC. | $106.52 | 2021 | |
| Amgen INC. | $100.26 | 2019 | |
| Livanova USA, INC. | $92.90 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $28.10 | 2023 | Arcalyst |
| Cvrx, INC. | $28.06 | 2023 | Barostim Neo System |
| Edwards Lifesciences Corporation | $25.13 | 2020 | |
| Allergan, INC. | $22.94 | 2019 | |
| Penumbra, INC. | $22.39 | 2021 | |
| Cardinal Health 200 LLC | $20.16 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.27 | 2019 | |
| Smith+Nephew, INC. | $17.69 | 2019 | |
| Biotronik INC. | $15.41 | 2024 | Orsiro Mission |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Colnes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.